Akèy › Leksemi mieloïd egi › Kalifòni
Etid klinik pou Leksemi mieloïd egi nan Kalifòni
79 etid pou Leksemi mieloïd egi ap chèche patisipan nan sit nan Kalifòni.
Vil nan Kalifòni
- Baldwin Park40 etid
- Los Angeles24 etid
- Mountain View19 etid
- Orange13 etid
- Sacramento12 etid
- San Francisco12 etid
- San Diego7 etid
- Oakland7 etid
- Roseville5 etid
- Fresno5 etid
- San Bernardino4 etid
- Santa Clara4 etid
- Long Beach4 etid
- Santa Rosa3 etid
- Concord3 etid
Tèks ofisyèl etid la (Anglè)
A Study to Assess Adverse Events and Change in Disease Activity When Intravenous (IV) Pivekimab Sunirine is Given in Combination With Oral Venetoclax and IV or Subcutaneous Azacitidine in Adult Participants With Acute Myeloid Leukemia (AML)
- City of Hope National Medical Center /ID# 279568, Duarte
Ap rekriteFaz 2/3
Laj 18 ak plis · Tout sèks · Mizajou Oct 2, 2026 · NCT07581002Olutasidenib With Azacitidine Followed by Olutasidenib Maintenance for the Treatment of IDH1-mutated Acute Myeloid Leukemia in Patients With Prior Treatment With Venetoclax Plus a Hypomethylating Agent
- UCI Health Chao Family Comprehensive Cancer Center, Orange
- University of California Davis Comprehensive Cancer Center, Sacramento
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Oct 2, 2026 · NCT07304011Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- Mission Hope Medical Oncology - Arroyo Grande, Arroyo Grande
- PCR Oncology, Arroyo Grande
- AIS Cancer Center at San Joaquin Community Hospital, Bakersfield
- ak 20 plis
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
Laj 40 a 75 · Tout sèks · Mizajou Oct 2, 2026 · NCT05334069A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies
- City of Hope, Duarte
- UC Davis, Sacramento
- Stanford Health Care, Stanford
Ap rekriteFaz 1
Laj 12 a 78 · Tout sèks · Mizajou Sep 29, 2026 · NCT03802695A Phase 1 Study of AOH1996 in Patients With Relapsed/Refractory Acute Myeloid Leukemia
- City of Hope Medical Center, Duarte
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 29, 2026 · NCT06763341Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)
- Cedars-Sinai Medical Center, Los Angeles
- Kaiser Permanente-Oakland, Oakland
- Kaiser Permanente-Roseville, Roseville
- ak 2 plis
Ap rekriteFaz 2
Laj 18 a 59 · Tout sèks · Mizajou Sep 28, 2026 · NCT05554393A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)
- City of Hope, Duarte
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT06852222MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
- Kaiser Permanente Dublin, Dublin
- Kaiser Permanente-Fremont, Fremont
- Kaiser Permanente Fresno Orchard Plaza, Fresno
- ak 21 plis
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT05564390Study of Revumenib in Combination With Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia (AML) With a NPM1 Mutation
- Clinical Trial Site, Duarte
Ap rekriteFaz 3
Laj 12 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT07211958Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)
- Kaiser Permanente Dublin, Dublin
- Kaiser Permanente-Fremont, Fremont
- Kaiser Permanente Fresno Orchard Plaza, Fresno
- ak 19 plis
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 22, 2026 · NCT06317649Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)
- UCSF Medical Center-Parnassus, San Francisco
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 22, 2026 · NCT06672146Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)
- Cedars-Sinai Medical Center, Los Angeles
- Kaiser Permanente-Oakland, Oakland
- Kaiser Permanente-Roseville, Roseville
- ak 3 plis
Ap rekriteFaz 2
Laj 18 a 59 · Tout sèks · Mizajou Sep 22, 2026 · NCT05554406A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
- Kaiser Permanente Downey Medical Center, Downey
- City of Hope Comprehensive Cancer Center, Duarte
- Loma Linda University Medical Center, Loma Linda
- ak 13 plis
Ap rekriteFaz 3
6 Months – 21 Years · Tout sèks · Mizajou Sep 17, 2026 · NCT04293562Evaluation of Two Dose Levels of Quizartinib as Maintenance in FLT3-ITD (+) Acute Myeloid Leukemia Patients in Complete Remission
- USC Norris Comprehensive Cancer Center, Los Angeles
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 16, 2026 · NCT06824168(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis
- City of Hope Comprehensive Cancer Center, Duarte
- UCLA Medical Center, Los Angeles
- Stanford Cancer Institute, Stanford
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 15, 2026 · NCT04996875Phase 1 Study of AUTX-703 in Relapsed/Refractory AML and MDS
- City of Hope National Medical Center, Duarte
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 14, 2026 · NCT06846606The Lowest Effective Dose of Post-Transplantation Cyclophosphamide in Combination With Sirolimus and Mycophenolate Mofetil as Graft-Versus-Host Disease Prophylaxis After Reduced Intensity Conditioning and Peripheral Blood Stem Cell Transplantation
- City of Hope, Duarte
Ap rekriteFaz 1/2Volontè an sante akeyi
Laj 12 a 120 · Tout sèks · Mizajou Sep 11, 2026 · NCT05436418A Study to Assess the Safety, Tolerability, and Antileukemic Activity of Debio 1562M in Participants With Acute Myeloid Leukemia (AML)
- City of Hope Comprehensive Cancer Center, Duarte
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 11, 2026 · NCT06969430A Study to Assess Adverse Events and How Intravenous (IV) Pivekimab Sunirine Moves Through the Body in Pediatric Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML)
- Lucile Packard Children's Hospital /ID# 276015, Palo Alto
Ap rekriteFaz 1
6 Months – 17 Years · Tout sèks · Mizajou Sep 9, 2026 · NCT07306832Xylitol Dental Wipes for the Reduction of Bloodstream Infection Risk in Children With Acute Myeloid Leukemia
- Valley Children's Hospital, Madera
- Kaiser Permanente-Oakland, Oakland
Ap rekriteFaz 3
Laj 1 a 25 · Tout sèks · Mizajou Sep 4, 2026 · NCT07022678Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML
- City of Hope National Medical Center, Duarte
Ap rekriteFaz 1/2
Laj 12 ak plis · Tout sèks · Mizajou Sep 3, 2026 · NCT04588922Revumenib in Combination With Azacitidine + Venetoclax in Patients NPM1-mutated or KMT2A-rearranged AML
- US-Los Angeles CA-UCLA, Los Angeles
- US-San Francisco CA-UCSF, San Francisco
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 2, 2026 · NCT06652438Bleximenib in Combination With Standard Induction and Consolidation Therapy Followed by Maintenance for Treatment of Patients With Acute Myeloid Leukemia (AML)
- US-Los Angeles CA-UCLA, Los Angeles
- US-San Francisco CA-UCSF, San Francisco
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 1, 2026 · NCT07223814MiRisten for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia
- City of Hope Medical Center, Duarte
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 1, 2026 · NCT07025564CER-1236 in Patients With Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), and Myelofibrosis (MF)
- University of California, Davis Comprehensive Cancer Center, Sacramento
Ap rekriteFaz 1
Laj 18 a 85 · Tout sèks · Mizajou Aug 26, 2026 · NCT06834282Eganelisib as Monotherapy and in Combination With Cytarabine in Relapsed/Refractory AML
- City of Hope, Duarte
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Aug 25, 2026 · NCT06533761A Phase 1b Study of Menin Inhibitor SNDX- 5613 in Combination With Daunorubicin and Cytarabine in Newly Diagnosed Patients With Acute Myeloid Leukemia and NPM1 Mutated/FLT3 Wildtype or MLL/KMT2A Rearranged or NUP98 Alterations Disease
- UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange
Ap rekriteFaz 1
Laj 18 a 75 · Tout sèks · Mizajou Aug 25, 2026 · NCT05886049The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
- Kaiser Permanente Downey Medical Center, Downey
- Loma Linda University Medical Center, Loma Linda
- Miller Children's and Women's Hospital Long Beach, Long Beach
- ak 8 plis
Ap rekriteFaz 1/2
Jiska laj 22 · Tout sèks · Mizajou Aug 25, 2026 · NCT04726241Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)
- MemorialCare Miller Children's and Women's Hospital Long Beach, Long Beach
- Children's Hospital of Orange County Main Campus - Orange, Orange
- Benioff Children's Hospital - Mission Bay, San Francisco
Ap rekriteFaz 3
29 Days – 21 Years · Tout sèks · Mizajou Aug 24, 2026 · NCT05183035Individualized AML Treatment
- City of Hope Medical Center, Duarte
Ap rekriteEtid obsèvasyon
Laj 18 ak plis · Tout sèks · Mizajou Aug 21, 2026 · NCT07613385Study of QUAIL-100 in Pediatric and Young Adult Participants With High-Risk Hematologic Malignancies Who Have Received a Hematopoietic Stem Cell Transplantation
- Lucille Packard Children's Hospital of Stanford University, Palo Alto
Ap rekriteFaz 1
18 Months – 39 Years · Tout sèks · Mizajou Aug 21, 2026 · NCT075731118-Chloroadenosine in Combination With Venetoclax for the Treatment of Patients With Relapsed/Refractory Acute Myeloid Leukemia
- City of Hope Medical Center, Duarte
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Aug 21, 2026 · NCT05263284Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
- University of California, Fresno, Clovis
- University of California, San Diego, La Jolla
- Cedars-Sinai Medical Center, Los Angeles
- ak 2 plis
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Aug 20, 2026 · NCT07007312Total Marrow and Lymphoid Irradiation in Combination With Fludarabine and Melphalan as Conditioning for Allogeneic Peripheral Blood Stem Cell Hematopoietic Cell Transplant in Older Patients With Refractory and Relapsed Acute Myeloid Leukemia and High-risk Myelodysplastic Syndrome
- City of Hope Medical Center, Duarte
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Aug 20, 2026 · NCT07582172Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
- USC Norris Comprehensive Cancer Center, Los Angeles
- UCLA Health - Bowyer Oncology Center, Los Angeles
- UC Irvine Health Chao Family Comprehensive Cancer Center, Orange
- ak 1 plis
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Aug 20, 2026 · NCT06001788ICP-248 in Combination With Azacitidine for the Treatment in Patients With Myeloid Malignancies
- Chao Family Comprehensive Cancer Center, University of California, Irvine, Orange
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Aug 18, 2026 · NCT06656494TACrolimus Targeted Immunosuppression Cessation in ALlogeneic HCT
- Stanford University, Palo Alto
Ap rekriteFaz 1
Laj 18 a 80 · Tout sèks · Mizajou Aug 17, 2026 · NCT07302776Niclosamide in Pediatric Patients With Relapsed and Refractory AML
- Stanford University, Palo Alto
Ap rekriteFaz 1
Laj 2 a 25 · Tout sèks · Mizajou Aug 12, 2026 · NCT05188170Olutasidenib DDI Study in Patients With IDH1 Mutation Positive Malignancies
- UCI Irvine Health, Orange
Ap rekriteFaz 4
Laj 18 ak plis · Tout sèks · Mizajou Aug 11, 2026 · NCT07486713Study of Revumenib, Azacitidine, and Venetoclax in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia
- Rady Children's Hospital, San Diego
Ap rekriteFaz 1
Laj 1 a 30 · Tout sèks · Mizajou Aug 3, 2026 · NCT06177067Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.